COMMUNIQUÉS West-GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
01/04/2024
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on [...]
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
01/04/2024
Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company [...]
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
01/04/2024
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, [...]
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
01/04/2024
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of [...]
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
01/04/2024
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported [...]
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
01/04/2024
Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval, Fractyl Health will [...]
Nxera Pharma is the New Name for Sosei Group
01/04/2024
New name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing medicines, by investing [...]
Total number of shares and voting rights in Zealand Pharma at March 31, 2024
31/03/2024
Company announcement – No. 21 / 2024 Total number of shares and voting rights in Zealand Pharma at March 31, 2024 Copenhagen, Denmark, March 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78 [...]
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
31/03/2024
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first paragraph it [...]
UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
29/03/2024
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on reversing aging in [...]
Information on the total number of voting rights and shares
29/03/2024
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), March 29, 2024 , 9:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the [...]
Informations sur le nombre total de droits de vote et d'actions
29/03/2024
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 29 mars 2024, 21:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
AEON Biopharma Announces Redemption of Public Warrants
29/03/2024
IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin [...]
Avalo Reports 2023 Financial Results and Provides Business Updates
29/03/2024
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million [...]
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29/03/2024
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – Topline data from [...]
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
29/03/2024
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial [...]
Range Impact Reports 4Q 2023 and Full Year 2023 Financial Results
29/03/2024
CLEVELAND, OHIO, March 29, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, [...]
NMDP Cycle Kicks Off Nationwide Cycling Events Giving Hope to Patients in Need of a Blood Stem Cell Transplant
29/03/2024
Riders can select from six routes to help raise funds and bring awareness to NMDP’s lifesaving mission MINNEAPOLIS, March 29, 2024 (GLOBE NEWSWIRE) -- NMDP SM Cycle (formerly Be The Match® Tour de TC) kicks off March 30 [...]
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
29/03/2024
- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more [...]

Pages